Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZOLEDRONIC vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits osteoclast-mediated bone resorption via binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase, disrupting the mevalonate pathway and inducing osteoclast apoptosis.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Treatment of osteoporosis in postmenopausal women,Treatment of osteoporosis in men,Treatment of glucocorticoid-induced osteoporosis,Paget's disease of bone,Hypercalcemia of malignancy,Prevention of skeletal-related events in multiple myeloma and bone metastases from solid tumors
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
5 mg intravenously over at least 15 minutes once yearly for the treatment of osteoporosis, Paget's disease, or hypercalcemia of malignancy; for prevention of skeletal-related events in multiple myeloma or bone metastases: 4 mg intravenously over at least 15 minutes every 3-4 weeks.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
The terminal elimination half-life of zoledronic acid is approximately 146 hours (range 44-196 hours) after a single intravenous dose. This long half-life reflects slow release from bone rather than systemic clearance. Despite the prolonged terminal phase, the clinical effect (suppression of bone resorption) persists for weeks to months. The initial distribution half-life is about 0.23 hours, and the intermediate half-life is about 1.75 hours.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Zoledronic acid is not metabolized in humans and is eliminated unchanged primarily by the kidneys via glomerular filtration and tubular secretion.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Zoledronic acid is excreted primarily unchanged by the kidneys via glomerular filtration and tubular secretion. Approximately 39 ± 16% of the administered dose is recovered in urine within 24 hours, with the remainder (up to 60%) retained in bone and slowly released over time. Fecal excretion is negligible (<1%). Renal clearance is dose-dependent and correlates with creatinine clearance. Dose adjustment is required for creatinine clearance <35 m L/min.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Zoledronic acid is approximately 22-40% bound to plasma proteins, primarily to albumin. Binding is concentration-independent over the therapeutic range, but the exact binding proteins are not fully characterized. The unbound fraction (60-78%) is pharmacologically active.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
The volume of distribution (Vd) is 4.3-7.6 L/kg (approximately 300-530 L in a 70 kg adult). This large Vd indicates extensive distribution into bone, where it binds to hydroxyapatite, and also to soft tissues. The Vd increases with body weight. The rapid initial distribution phase reflects high affinity for bone (exposed hydroxyapatite surfaces).
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Zoledronic acid has negligible oral bioavailability (<0.5%) due to high polarity and poor intestinal absorption. Only intravenous administration is used clinically (IV infusion over at least 15 minutes for the 4 mg dose or 30-60 minutes for higher doses). Subcutaneous, intramuscular, and other routes are not recommended due to risk of local reactions and incomplete absorption.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
For osteoporosis: not recommended if Cr Cl <35 m L/min. For Paget's disease or hypercalcemia: not recommended if Cr Cl <35 m L/min. For malignancy-related bone disease: if Cr Cl 30-60 m L/min, reduce dose to 3.5 mg; if Cr Cl <30 m L/min, not recommended. All doses should be administered only after correcting hypovolemia and monitoring serum creatinine.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No dose adjustment required for mild to moderate hepatic impairment; not studied in severe hepatic impairment, use with caution.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Not recommended for use in pediatric patients; safety and efficacy not established.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
No specific dose adjustment required based on age alone; renal function should be assessed and dose adjusted accordingly as elderly patients are more likely to have decreased renal function.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Zoledronic acid is not recommended for use in patients with severe renal impairment (Cr Cl <35 m L/min) due to increased risk of renal toxicity. Acute renal failure and renal impairment may occur after single or multiple doses, especially in patients with pre-existing renal disease or dehydration.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Renal toxicity and acute renal failure, particularly in patients with impaired renal function or dehydration,Electrolyte disturbances (e.g., hypocalcemia, hypophosphatemia, hypomagnesemia),Osteonecrosis of the jaw (ONJ), especially in cancer patients with dental risk factors,Atypical femur fractures with long-term use,Severe musculoskeletal pain,Bronchospasm in aspirin-sensitive asthmatic patients
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypocalcemia,Severe renal impairment (Cr Cl <35 m L/min),Pregnancy (category D),Breastfeeding,Hypersensitivity to zoledronic acid or any component of the formulation
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid high-calcium foods (e.g., dairy, fortified cereals) within 2 hours of taking oral calcium supplements; however, no direct food interactions with IV zoledronic acid. Maintain adequate calcium and vitamin D intake as part of therapy.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Zoledronic acid (a bisphosphonate) is FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and limited human data. In animal studies, it caused skeletal and visceral anomalies, reduced fetal weight, and increased fetal mortality. Use is contraindicated in pregnancy due to risk of fetal skeletal abnormalities and hypocalcemia. First trimester exposure carries the highest risk for skeletal teratogenicity. Second and third trimester exposure may cause fetal hypocalcemia and bone demineralization.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
It is unknown if zoledronic acid is excreted in human breast milk. Due to potential for bone growth suppression and hypocalcemia in the infant, breastfeeding is not recommended during therapy and for at least 1 month after the last dose. M/P ratio is not available.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific dosing adjustments are recommended because zoledronic acid is contraindicated in pregnancy. If used inadvertently, no dosage adjustment is advised; therapy should be discontinued. Pregnancy may alter pharmacokinetics (increased volume of distribution, renal clearance), but data insufficient to guide dose changes.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Monitor serum creatinine before each dose; avoid in Cr Cl <35 m L/min. Assess for hypocalcemia and correct vitamin D deficiency before initiation. Administer as a 15-minute IV infusion; do not bolus. Use with caution in patients with asthma (aspirin-sensitive) due to risk of bronchospasm. For osteoporosis, ensure adequate calcium and vitamin D intake. Acute phase reaction (fever, myalgia) common after first dose; premedicate with acetaminophen if needed.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
You may experience flu-like symptoms (fever, muscle pain) after your first infusion; this usually resolves in 1-3 days.,Take calcium and vitamin D supplements as directed to prevent low calcium levels.,Drink plenty of water before and after infusion to protect your kidneys.,Report any jaw pain, numbness, or swelling; this could be a sign of osteonecrosis of the jaw.,Avoid dental procedures (extractions, implants) for at least 3 months after your dose.,This medication is given by intravenous infusion every 3-4 weeks for cancer or once yearly for osteoporosis.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Concomitant use of olopatadine, an antihistamine with weak anticholinergic properties, and zoledronic acid, a bisphosphonate, may lead to an increased risk of renal toxicity. Olopatadine can cause urinary retention, while zoledronic acid is primarily eliminated unchanged by the kidneys; additive nephrotoxic effects may occur, particularly in patients with pre-existing renal impairment or dehydration. This interaction may result in elevated serum creatinine, acute kidney injury, or renal failure."
"Tranilast, an antiallergic agent, may increase the risk of nephrotoxicity when coadministered with zoledronic acid, a bisphosphonate primarily eliminated by renal excretion. This interaction could lead to elevated serum creatinine and acute kidney injury, particularly in patients with pre-existing renal impairment or dehydration. Clinical outcomes may include delayed renal recovery or prolonged hospitalization."
"The coadministration of Nabumetone, a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits cyclooxygenase (COX) enzymes, and Zoledronic acid, a bisphosphonate that inhibits osteoclast-mediated bone resorption, may lead to an increased risk of renal adverse effects, particularly acute kidney injury (AKI). Nabumetone can reduce renal prostaglandin synthesis, leading to decreased renal blood flow and glomerular filtration rate, which may impair the elimination of Zoledronic acid and exacerbate its nephrotoxic potential. This interaction is especially concerning in patients with pre-existing renal impairment, dehydration, or those taking other nephrotoxic medications."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ZOLEDRONIC vs ACTIQ, answered by our medical review team.
ZOLEDRONIC is a Bisphosphonate that works by Inhibits osteoclast-mediated bone resorption via binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase, disrupting the mevalonate pathway and inducing osteoclast apoptosis.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ZOLEDRONIC and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ZOLEDRONIC is: 5 mg intravenously over at least 15 minutes once yearly for the treatment of osteoporosis, Paget's disease, or hypercalcemia of malignancy; for prevention of skeletal-related events in multiple myeloma or bone metastases: 4 mg intravenously over at least 15 minutes every 3-4 weeks.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ZOLEDRONIC and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ZOLEDRONIC is classified as Category C. Zoledronic acid (a bisphosphonate) is FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and limited human data. In animal studies, it caused skeleta. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.